Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Trimmed by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lessened its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 19.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 63,220 shares of the biopharmaceutical company's stock after selling 14,875 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.07% of Ultragenyx Pharmaceutical worth $2,660,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. True Wealth Design LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $43,000. Values First Advisors Inc. acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth $56,000. Wilmington Savings Fund Society FSB acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth $83,000. Nomura Asset Management Co. Ltd. acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth $93,000. Finally, Capital Performance Advisors LLP acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth $107,000. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Trading Down 2.1 %

RARE traded down $0.85 on Friday, hitting $40.00. 794,367 shares of the company's stock were exchanged, compared to its average volume of 1,213,560. The firm has a market cap of $3.69 billion, a PE ratio of -6.18 and a beta of 0.58. Ultragenyx Pharmaceutical Inc. has a twelve month low of $37.02 and a twelve month high of $60.37. The stock has a fifty day moving average of $45.30 and a two-hundred day moving average of $49.52.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The firm had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. During the same quarter in the prior year, the business earned ($2.23) earnings per share. Ultragenyx Pharmaceutical's quarterly revenue was up 42.3% on a year-over-year basis. On average, analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.21 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. HC Wainwright reiterated a "buy" rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. Canaccord Genuity Group restated a "buy" rating and issued a $121.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. JPMorgan Chase & Co. cut their target price on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating on the stock in a research note on Thursday, November 21st. Finally, TD Cowen upped their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a "buy" rating in a research note on Monday, October 21st. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $92.29.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 8,273 shares of the company's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total value of $413,650.00. Following the completion of the transaction, the chief executive officer now owns 2,195,712 shares in the company, valued at approximately $109,785,600. This represents a 0.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.80% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.